Análisis Argos
SGRY
SGRYBarata · ojo al riesgo1 señal de riesgo
Surgery Partners, Inc. · Healthcare
US$ 17.23
precio al 2026-07-04
Valor justo Argos*
US$ 19–21
vs. su valor justo
18% por debajo
Score Argos
49/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 1.2% al año — menos de lo que viene demostrando (4.8%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
✓Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Altman Z'' en zona roja (0.8)
VALOR4/6FUTURO3/6PASADO2/6SALUD1/6DIVIDENDO1/6
El Iris de calidad
VALOR4/6FUTURO3/6PASADO2/6SALUD1/6DIVIDENDO1/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos49de 100Barata · ojo al riesgo
Ingresos▲6%
US$ 3.3 B
Margen operativo▲5%
11.8%
Flujo de caja libre▼5%
US$ 0.2 B
Deuda neta
US$ 3.8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 2.3B
P/E—
EV/EBITDA10.7x
FCF yield8.7%
ROIC6%
Margen operativo11.8%
Crecim. ingresos+6.2%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 22 jun
Why Fast-paced Mover Surgery Partners (SGRY) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Surgery Partners (SGRY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com · 18 jun
Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
fool.com · 10 jun
Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?
Surgery Partners operates a massive nationwide network of outpatient surgical facilities and hospitals. Viemed Healthcare is a high-growth specialist focusing on home-based respiratory care and disease management.
seekingalpha.com · 5 may
Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
zacks.com · 5 may
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago.
globenewswire.com · 5 may
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026.
globenewswire.com · 5 may
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
BRENTWOOD, Tenn. , May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ: SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 4.
zacks.com · 22 abr
AUNA vs. SGRY: Which Hospital Stock Looks More Attractive Now?
Auna S.A. gains from Peru growth, stabilizing Mexico and Colombia cash flow focus, while Surgery Partners faces earnings cuts and headwinds.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.